Donepezil |
Improving cognition and function, delaying institutionalization |
Moderate |
Acetylcholinesterase inhibitor |
[249] |
Rivastigmine |
Improving cognition and function, delaying institutionalization |
Moderate |
Acetylcholinesterase inhibitor |
[250] |
Galantamine |
Improving cognition and function, delaying institutionalization |
Moderate |
Acetylcholinesterase inhibitor and allosteric modulator of nicotinic receptors |
[251] |
Memantine |
Improving cognition and function, delaying institutionalization |
Moderate |
NMDA receptor antagonist |
[252] |
Solanezumab |
Slowing down degeneration process through increasing Aβ clearance |
Limited |
Remove soluble Aβ |
[253] |
Memantine and donepezil |
Memantine plus donepezil showing superior outcomes |
Limited |
Combination of acetylcholinesterase inhibitor and NMDA receptor antagonist |
[254] |
Huperzine A |
Improving cognition and function |
Limited |
Acetylcholinesterase inhibitor |
[255] |
Ginkgo biloba |
Improving cognition and function |
Limited |
Antioxidant, anti-inflammatory, and circulatory effects |
[256] |
NSAIDs |
No significant effect on cognition or overall AD severity. |
Limited |
Anti-inflammatory effect |
[257] |
Statins |
May reduce risk of Alzheimer's disease |
Limited |
Cholesterol-lowering effect |
[258] |
Antidepressants |
Improving mood and reducing behavioral symptoms |
Limited |
Various mechanisms |
[259] |